Update in TSH receptor agonists and antagonists

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4287-4292

  Gershengorn, Marvin C ^a   Neumann, Susanne ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 [(2,6 DIMETHYLPHENOXY)METHYL] 4 METHOXYPHENYL] 3 (FURAN 2 YLMETHYL) 2,3 DIHYDROQUINAZOLIN 4(1H) ONE; 2 [3 [(2,6 DIMETHYLPHENOXY)METHYL] 4 METHOXYPHENYL] 3 (PYRIDIN 3 YLMETHYL) 2,3 DIHYDROQUINAZOLIN 4(1H) ONE; 2 [3 [(2,6 DIMETHYLPHENYLTHIO)METHYL] 4 METHOXYPHENYL] 3 (FURAN 2 YLMETHYL) 2,3 DIHYDROQUINAZOLIN 4(1H) ONE; AROCLOR 1254; CHLORPHENOTANE; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; N (1 ACETYL 4 METHYL 4 PHENYL 1,2,3,4 TETRAHYDRO QUINOLIN 6 YL) 3 (3 TRIFLUOROMETHYLPHENYL)PROPIONAMIDE; N [4 [5 (3 BENZYL 5 HYDROXY 4 OXO 1,2,3,4 TETRAHYDROQUINAZOLIN 2 YL) 2 METHOXYBENZYLOXY]PHENYL]ACETAMIDE; NCGC 00161856; NCGC 00161870; NCGC 00229600; NCGC 00242595; NIDDK CEB 52; ORG 274179 0; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HYPOTHYROIDISM; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW;

ANIMALS; ANTITHYROID AGENTS; DRUG DISCOVERY; ENDOCRINOLOGY; HORMONE ANTAGONISTS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; RECEPTORS, THYROTROPIN; THYROID DISEASES;

EID: 84870754593     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3080     Document Type: Review

References (33)

1. Bassett JH, Williams GR 2008 Critical role of the hypothalamicpituitary- thyroid axis in bone. Bone 43:418-426
2. Blair HC, Robinson LJ, Sun L, Isales C, Davies TF, Zaidi M 2011 Skeletal receptors for steroid-family regulating glycoprotein hormones: a multilevel, integrated physiological control system. Ann NY Acad Sci 1240:26-31
3. Bassett JH, Williams AJ, Murphy E, Boyde A, Howell PG, Swinhoe R, Archanco M, Flamant F, Samarut J, Costagliola S, Vassart G, Weiss RE, Refetoff S, Williams GR 2008 A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol 22:501-512 (Pubitemid 351185945)
4. Davies TF, Ando T, Lin RY, Tomer Y, Latif R 2005 Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest 115:1972-1983 (Pubitemid 41134132)
5. Rapoport B, McLachlan SM 2007 The thyrotropin receptor in Graves' disease. Thyroid 17:911-922 (Pubitemid 350071596)
6. Bahn RS 2010 Graves' ophthalmopathy. N Engl J Med 362:726-738
7. Duprez L, Parma J, Van Sande J, Rodien P, Dumont JE, Vassart G, Abramowicz M 1998 TSH receptor mutations and thyroid disease. Trends Endocrinol Metab 9:133-140 (Pubitemid 28252603)
8. Refetoff S 2003 Resistance to thyrotropin. J Endocrinol Invest 26:770-779 (Pubitemid 37441509)
9. Almandoz JP, Gharib H 2012 Hypothyroidism: etiology, diagnosis, and management. Med Clin North Am 96:203-221
10. Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA 2011 Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108:1615-1620
11. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H 2008 Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93:809-814 (Pubitemid 351398557)
12. Pacini F, Castagna MG 2008 Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 22:1009-1021
13. Duntas LH, Cooper DS 2008 Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid 18:509-516 (Pubitemid 351667835)
14. Woodmansee WW, Haugen BR 2004 A review of the potential uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clin Endocrinol (Oxf) 61:163-173 (Pubitemid 39093110)
15. Fast S, Nielsen VE, Grupe P, Boel-Jørgensen H, Bastholt L, Andersen PB, Bonnema SJ, Hegedüs L 2012 Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter. J Clin Endocrinol Metab 97:2653-2660
16. Sanders J, Miguel RN, Furmaniak J, Rees Smith B 2010 TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities. Methods Enzymol 485:393-420
17. Vassart G, Pardo L, Costagliola S 2004 A molecular dissection of the glycoprotein hormone receptors. Trends Biochem Sci 29:119-126 (Pubitemid 38314857)
18. Jäschke H, Neumann S, Moore S, Thomas CJ, Colson AO, Costanzi S, Kleinau G, Jiang JK, Paschke R, Raaka BM, Krause G, Gershengorn MC 2006 A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J Biol Chem 281:9841-9844 (Pubitemid 43864515)
19. Neumann S, Kleinau G, Costanzi S, Moore S, Jiang JK, Raaka BM, Thomas CJ, Krause G, Gershengorn MC 2008 A low-molecularweight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology 149:5945-5950
20. Moore S, Jaeschke H, Kleinau G, Neumann S, Costanzi S, Jiang JK, Childress J, Raaka BM, Colson A, Paschke R, Krause G, Thomas CJ, Gershengorn MC 2006 Evaluation of small-molecule modulators of the luteinizing hormone/choriogonadotropin and thyroid stimulating hormone receptors: structure-activity relationships and selective binding patterns. J Med Chem 49:3888-3896 (Pubitemid 43967885)
21. Titus S, Neumann S, Zheng W, Southall N, Michael S, Klumpp C, Yasgar A, Shinn P, Thomas CJ, Inglese J, Gershengorn MC, Austin CP 2008 Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. J Biomol Screen 13:120-127 (Pubitemid 351248693)
22. Neumann S, Huang W, Titus S, Krause G, Kleinau G, Alberobello AT, Zheng W, Southall NT, Inglese J, Austin CP, Celi FS, Gavrilova O, Thomas CJ, Raaka BM, Gershengorn MC 2009 Small molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc Natl Acad Sci USA 106:12471-12476
23. Kleinau G, Haas AK, Neumann S, Worth CL, Hoyer I, Furkert J, Rutz C, Gershengorn MC, Schülein R, Krause G 2010 Signaling-sensitive amino acids surround the allosteric ligand binding site of the thyrotropin receptor. FASEB J 24:2347-2354
24. Haas AK, Kleinau G, Hoyer I, Neumann S, Furkert J, Rutz C, Schülein R, Gershengorn MC, Krause G 2011 Mutations that silence constitutive signaling activity in the allosteric ligand-binding site of the thyrotropin receptor. Cell Mol Life Sci 68:159-167
25. Allen MD, Neumann S, Gershengorn MC 2011 Small-molecule thyrotropin receptor agonist activates naturally occurring thyrotropininsensitive mutants and reveals their distinct cyclic adenosine monophosphate signal persistence. Thyroid 21:907-912
26. Rossi M, Dimida A, Dell'anno MT, Trincavelli ML, Agretti P, Giorgi F, Corsini GU, Pinchera A, Vitti P, Tonacchera M, Maggio R 2007 The thyroid disruptor 1,1,1-trichloro-2,2-bis(p-chlorophenyl)-ethane appears to be an uncompetitive inverse agonist for the thyrotropin receptor. J Pharmacol Exp Ther 320:465-474 (Pubitemid 46039605)
27. Rossi M, Dimida A, Ferrarini E, Silvano E, De Marco G, Agretti P, Aloisi G, Simoncini T, Di Bari L, Tonacchera M, Giorgi F, Maggio R 2009 Presence of a putative steroidal allosteric site on glycoprotein hormone receptors. Eur J Pharmacol 623:155-159
28. van Koppen CJ, de Gooyer ME, Karstens WJ, Plate R, Conti PG, van Achterberg TA, van Amstel MG, Brands JH, Wat J, Berg RJ, Lane JR, Miltenburg AM, Timmers CM 2012 Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor. Br J Pharmacol 165:2314-2324
29. van Zeijl CJ, van Koppen CJ, Surovtseva OV, de Gooyer ME, Plate R, Conti P, Karstens WJ, Timmers M, Saeed P, Wiersinga WM, Miltenburg AM, Fliers E, Boelen A 2012 Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist. J Clin Endocrinol Metab 97:E781-E785
30. Sanders J, Evans M, Premawardhana LD, Depraetere H, Jeffreys J, Richards T, Furmaniak J, Rees Smith B 2003 Human monoclonal thyroid stimulating autoantibody. Lancet 362:126-128 (Pubitemid 36831025)
31. Boutin A, Allen MD, Geras-Raaka E, Huang W, Neumann S, Gershengorn MC 2011 Thyrotropin receptor stimulates internalization-independent persistent phosphoinositide signaling. Mol Pharmacol 80:240-246
32. Neumann S, Eliseeva E, McCoy JG, Napolitano G, Giuliani C, Monaco F, Huang W, Gershengorn MC 2011 A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor. J Clin Endocrinol Metab 96:548-554
33. Neumann S, Pope A, Geras-Raaka E, Raaka BM, Bahn RS, Gershengorn MC 2012 A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts. Thyroid 22:839-843